BioPharmX Corp fka BPMX

[Whos_Who]

David Tierney commented, “BioPharmX is on the threshold of an important and exciting growth phase as is evident from the company’s robust product pipeline and its lead product candidate being phase 3-ready for acne.” He further noted, “I expect advancements in BioPharmX product development to drive increased corporate visibility and transformational changes in dermatologic pharmaceuticals. I am thrilled to have the opportunity to participate and contribute to BioPharmX’s growth prospects.”